Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Caris Life Sciences Inc banner
C

Caris Life Sciences Inc
NASDAQ:CAI

Watchlist Manager
Caris Life Sciences Inc
NASDAQ:CAI
Watchlist
Price: 21.415 USD -4.61% Market Closed
Market Cap: $6B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

CAI Price Targets Summary
Caris Life Sciences Inc

Wall Street analysts forecast CAI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CAI is 38.647 USD with a low forecast of 30.3 USD and a high forecast of 47.25 USD.

CAI Lowest Forecast
Wall Street Target
30.3 USD
41% Upside
CAI Average Forecast
Wall Street Target
38.647 USD
80% Upside
CAI Highest Forecast
Wall Street Target
47.25 USD
121% Upside
Lowest
Price Target
30.3 USD
41% Upside
Average
Price Target
38.647 USD
80% Upside
Highest
Price Target
47.25 USD
121% Upside
Caris Life Sciences Inc Competitors:
Price Targets
OFIX
Orthofix Medical Inc
53% Upside
ACAD
ACADIA Pharmaceuticals Inc
45% Upside
SAVA
Cassava Sciences Inc
149% Upside
WLFC
Willis Lease Finance Corp
-18% Downside
OFIX
Orthofix Medical Inc
53% Upside
ACAD
ACADIA Pharmaceuticals Inc
45% Upside
SAVA
Cassava Sciences Inc
149% Upside
WLFC
Willis Lease Finance Corp
-18% Downside

Revenue
Forecast

N/A
Past Growth
36% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
36% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

The compound annual growth rate of Caris Life Sciences Inc's revenue for the next 4 years is 36%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

What are analyst estimates?

See Also

Summary
CAI intrinsic value, competitors valuation, and company profile.
DCF Valuation
CAI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CAI stock valuation using valuation multiples.
Wall Street Estimates
CAI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CAI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CAI's stock price target?
Price Target
38.647 USD

According to Wall Street analysts, the average 1-year price target for CAI is 38.647 USD with a low forecast of 30.3 USD and a high forecast of 47.25 USD.

What is Caris Life Sciences Inc's Revenue forecast?
Projected CAGR
36%

The compound annual growth rate of Caris Life Sciences Inc's revenue for the next 4 years is 36%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 317,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.